FindTrial
Sign In

Analysis of comorbidity, general condition and risk factors of 803 consecutive patients with multiple myeloma: development and weighting of a myeloma-specific risk score compared with established comorbidity indices

Analysis of comorbidity, general condition and risk factors of 803 consecutive patients with multiple myeloma: development and weighting of a myeloma-specific risk score compared with established comorbidity indices

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00009237
Enrollment
803
Registered
2015-10-16
Start date
2013-02-25
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C90.0

Interventions

Group 1: We have identified an impaired Karnofsky Performance Status (KPS), lung- and renal-impairment as significant risks for inferior outcome. These variables were combined in a comorbidity score (

Sponsors

Universitätsklinikum Freiburg
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with multiple myeloma, treated at our institution between 1997-2012.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

MeasureTime frame
Determining comorbidities as weighted renal-, lung-, heart-, liver-, gastrointestinal diseases, KPS, disability, frailty, infection, pain, secondary malignancies, peripheral neuropathy, thrombosis and disease parameters (e.g. cytogenetics).—

Countries

Germany

Contacts

Public ContactMonika Engelhardt Engelhardt

Uniklinik Freiburg

monika.engelhardt@uniklinik-freiburg.de+49 761 270 32460

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026